Question 1 · Hard
A 52-year-old man, 3 months after an allogeneic stem cell transplant for leukemia, was not vaccinated this season and has influenza A(H1N1)pdm09 pneumonia confirmed by RT-PCR on a nasopharyngeal swab, and oseltamivir is started. Repeat nasopharyngeal swabs are tested with the same assay and collection method: day 0, Ct 29; day 5, Ct 27; day 10, Ct 24, each with a valid internal control. He remains hypoxic on day 10. Which laboratory test is most useful now?
- APaired serology for influenza A antibodies
- BHemagglutinin subtyping to confirm H1N1pdm09
- CNeuraminidase gene testing for the H275Y mutation
- DA rapid antigen test to confirm the PCR
Show answerHide answer
Answer: C · Neuraminidase gene testing for the H275Y mutation
A falling Ct means a rising amount of viral RNA, so the virus is still replicating after 10 days of oseltamivir. Immunocompromised patients shed influenza for long periods and are the group in whom antiviral resistance most often emerges during treatment. In A(H1N1)pdm09, the commonest oseltamivir-resistance change is H275Y in the neuraminidase (H274Y in N2 numbering), detected by targeted RT-PCR or sequencing. This mutation usually leaves zanamivir active, so the result directly guides treatment. Subtyping, serology and antigen tests cannot detect resistance.
- A: Serology is slow, may fail after transplant and does not detect resistance.
- B: The subtype is already known and does not explain the rising viral load.
- D: A rapid antigen test is less sensitive than PCR and gives no resistance result.